Lipitor's Protein Binding Basics
Lipitor (atorvastatin) binds 80-90% to plasma proteins, mainly albumin.[1] This high binding means most of the drug circulates bound and inactive, with only the unbound fraction (10-20%) available for pharmacological effects, metabolism, or elimination.
Removal During Kidney Dialysis
Lipitor is not significantly removed by hemodialysis due to its high protein binding and large molecular weight (558 Da).[1][2] Dialysis membranes allow passage of small, unbound molecules like urea or creatinine, but bound drugs like Lipitor stay in the blood. Studies show negligible dialyzability—less than 2% of the dose is extracted per session.[3]
Clinical Implications for Dialysis Patients
Patients on dialysis have reduced Lipitor clearance, raising risks of accumulation if doses aren't adjusted.[2] Guidelines recommend starting at lower doses (e.g., 10 mg daily) and monitoring for statin myopathy or rhabdomyolysis, as impaired kidney function already heightens these risks.[4] No dose adjustment is needed solely for dialysis, but total clearance drops by about 30-50% in end-stage renal disease.[1]
Comparison to Other Statins
Unlike highly protein-bound statins like simvastatin (95%) or rosuvastatin (88%), which also resist dialysis removal, pravastatin (50% bound) is more dialyzable and may require post-dialysis dosing.[3] This makes Lipitor's profile typical for dialysis but demands caution in polypharmacy.
Patient Monitoring and Alternatives
Track CK levels and symptoms like muscle pain in dialysis patients on Lipitor. Alternatives like ezetimibe or PCSK9 inhibitors offer lipid control with less renal dependence.[4]
[1]: Lipitor Prescribing Information (Pfizer)
[2]: Kidney International - Statin Pharmacokinetics in CKD
[3]: Clinical Pharmacokinetics - Dialyzability of Statins
[4]: KDIGO Dyslipidemia Guidelines